Waiting Game For Minerva After Roluperidone US Filing
Decision On Filing Acceptance Due In 60 Days
The firm’s potential new therapy for the negative symptoms of schizophrenia is now in the hands of the US Food and Drug Administration – some have concerns over whether the supporting data will be enough.
